-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 25, 2021 // --Recently, a research report entitled "Targeting loss of heterozygosity for cancer-specific immunotherapy" was published in the international journal PNAS , from Johns Hopkins University School of Medicine and other institutions Through research, scientists have developed a prototype of a new type of cancer immunotherapy, which may be able to engineer T cells to target all common genetic alterations in cancer; this new method can stimulate the body’s The immune response protects cells that lack a copy of a gene, that is, cells with loss of heterozygosity (LOH).
PNAS scientists from Johns Hopkins University School of Medicine and other institutions have developed a new type of cancer immunotherapy prototype through research, which may be able to engineer T cells to target all common genetic mutations in cancer ( genetic alteration); this new method can stimulate the body's immune response to resist cells that lack a copy of a gene, that is, cells with loss of heterozygosity (LOH).
jpg">
A gene has two alleles or copies, and the two copies are from the parent's body; cancer-related genetic changes usually involve the loss of one of the gene copies.
CARs are engineered receptors that can bind to special antigens on the surface of cancer cells.
The researcher Michael Hwang explained that in normal cells, both alleles are present and expressed.
The researchers tested the NASCAR therapy in three separate cell lines and mouse models, including mouse models with or without LOH, to confirm the specificity of this method for genetic changes.
Image source: Elizabeth Cook
Researcher Shibin Zhou said that the research in this article provides a principled proof that this method can be used to selectively kill cancer cells; researchers may need to conduct years of research before clinical implementation.
The research in this article provides a principled proof that this method can be used to selectively kill cancer cells; before clinical implementation, researchers may need to conduct years of research, and assemble and comprehensively test all groups.
Reference materials:
Reference materials:[1] Michael S.
[1] Michael S.
【2】com/news/2021-03-cancer-immunotherapy-approach-common-genetic.
by Johns Hopkins University School of Medicine
